🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are escalating globally, with estimates suggesting more than 82 million infections annually. Particularly high rates are reported in Africa and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the reality of rising global incidence, escalating drug resistance and the very limited treatment choices at this time.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Drugs Gain Approval

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists believe that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in the same week. This drug, which is also used to treat urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment stemmed from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to bring it to fruition.

“This authorization signifies a huge turning point in the management of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Data and Worldwide Availability

Based on data detailed in a prominent scientific publication, the new drug successfully treated more than 90% of cases of the STI. This puts it on an equal footing with the typical regimen, which involves two antibiotics. The research enrolled nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the rights to license and sell the drug in many regions with limited resources.

Clinicians directly involved have voiced hope. Having a single-dose, oral treatment like this is seen as a "critical tool" for public health efforts. This is viewed as vital to reduce the burden of the disease for people and to prevent the spread of untreatable gonorrhoea globally.